M2 Pharma - Therapy Areas - Inflammatory Disease

Sebacia awarded US FDA clearance for Sebacia Microparticles acne treatment

18 September 2018 - Dermatology company Sebacia, Inc revealed on Monday that it has passed US Food and Drug Administration (FDA) clearance for its lead product, Sebacia Microparticles for the treatmen...

Pfizer Touts Positive Phase 2 Data in Alopecia Areata

17 September 2018 - - US-based biopharmaceutical company Pfizer Inc. (NYSE: PFE) has released results from its Phase 2a study of PF-06651600, an oral Janus kinase 3 inhibitor, and PF-06700841, a tyros...

Pfizer presents phase 2 Alopecia Areata treatment data at European meeting

17 September 2018 - Pfizer Inc (NYSE:PFE) a US-based pharmaceutical company announced on Saturday results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-0670084...

CEL-SCI Receives USD 5.4m from warrant Exercises

14 September 2018 - - US-based drug and vaccine developer CEL-SCI Corp. (NYSE American: CVM) has received USD 5,435,367 through the exercise of warrants to purchase shares of the company�...

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis, a Rare form of Juvenile Arthritis

14 September 2018 - - The US Food and Drug Administration has approved the subcutaneous formulation of Actemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis in ...

Janssen's Tremfya Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis

13 September 2018 - - The Janssen Pharmaceutical Companies of Johnson and Johnson (NYSEL JNJ) has released new data that show considerable improvements in long-term patient-reported outcomes in patien...